Ascelia Pharma to present at Redeye seminar in Malmö on 12 September 2019


On 12th of September, Ascelia Pharma’s CEO Magnus Corfitzen will present the latest development in the company at Redeye’s afterwork event in Malmö. The presentation will be held at Clarion Hotel & Congress Malmö Live and Ascelia Pharma will start its presentation at 6pm CET.

The presentation can also be followed live via:

Program and registration for the event can be found here:

For more information, please contact:
Mikael Widell, IR & Communications Manager
Tel: +46 703 11 99 60

The information was submitted for publication, through the agency of the contact person set out above, at 9.15am CET on 11 September 2019.

About Ascelia Pharma
Ascelia Pharma is an oncology-dedicated orphan drug development company located in Malmö, Sweden. The company’s strategy is to develop drugs, which target unmet medical needs, have an established mode of action and a relatively low development risk. Ascelia Pharma has two drug candidates – Mangoral® and Oncoral – currently under development.

Mangoral is a novel contrast agent for MR-scans and is ready for Phase III clinical studies. Mangoral is developed to improve the visualization of focal liver lesions (liver metastases) in patient with impaired kidneys that cannot tolerate current gadolinium contrast agents on the market. Oncoral is an oral chemotherapy tablet ready for Phase II for the treatment of gastric cancer. Ascelia Pharma is listed on Nasdaq Stockholm (ticker: ACE). For more information, please visit


Vator Securities: Ascelia Pharma: A rocket roll out is the key to success

February 20, 2020

First patient enrolled in pivotal Phase III clinical study SPARKLE with lead candidate Mangoral

Ascelia Pharma AB (publ) (ticker: ACE) today announced that the first patient has been enrolled in the company’s global pivotal Phase III clinical study SPARKLE with Mangoral in patients with severely reduced renal function and with known or suspected liver lesions.

2019 year-end financial report: Sites opened for recruitment to the pivotal Phase III study SPARKLE

Ascelia Pharma AB (publ) (ticker: ACE) today published its year-end report for the period July 2019 – December 2019, which is now available on the company’s website (the financial year will going forward follow the calendar year):